LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Lowered by StockNews.com

LeMaitre Vascular (NASDAQ:LMAT) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

Other research analysts have also issued reports about the company. JMP Securities increased their price objective on LeMaitre Vascular from $72.00 to $77.00 and gave the stock a “market outperform” rating in a research note on Friday, May 3rd. Roth Mkm restated a “buy” rating and issued a $100.00 target price on shares of LeMaitre Vascular in a research note on Friday, May 31st. Roth Capital upgraded LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and raised their target price for the company from $59.00 to $75.00 in a research note on Friday, April 26th. Finally, Barrington Research lifted their price objective on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, LeMaitre Vascular has an average rating of “Moderate Buy” and a consensus target price of $77.57.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $85.83 on Thursday. The stock has a market cap of $1.93 billion, a P/E ratio of 56.84, a price-to-earnings-growth ratio of 2.75 and a beta of 0.89. LeMaitre Vascular has a one year low of $44.27 and a one year high of $91.76. The stock has a fifty day moving average price of $81.97 and a 200 day moving average price of $70.60.

LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 EPS for the quarter, topping the consensus estimate of $0.39 by $0.05. The firm had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. LeMaitre Vascular’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same period last year, the business earned $0.27 earnings per share. Equities research analysts anticipate that LeMaitre Vascular will post 1.77 EPS for the current year.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,030 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at approximately $168,944,956.56. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO George W. Lemaitre sold 27,030 shares of LeMaitre Vascular stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the sale, the chief executive officer now directly owns 1,958,328 shares of the company’s stock, valued at $168,944,956.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Bridget A. Ross sold 5,500 shares of the firm’s stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $77.99, for a total value of $428,945.00. Following the transaction, the director now owns 2,278 shares of the company’s stock, valued at $177,661.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 127,437 shares of company stock valued at $10,076,242. 10.79% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On LeMaitre Vascular

A number of hedge funds have recently added to or reduced their stakes in the business. YHB Investment Advisors Inc. acquired a new stake in LeMaitre Vascular in the first quarter valued at approximately $36,000. SRS Capital Advisors Inc. boosted its position in shares of LeMaitre Vascular by 325.5% during the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 524 shares during the last quarter. GAMMA Investing LLC boosted its position in shares of LeMaitre Vascular by 57.0% during the second quarter. GAMMA Investing LLC now owns 548 shares of the medical instruments supplier’s stock valued at $45,000 after buying an additional 199 shares during the last quarter. West Oak Capital LLC purchased a new position in shares of LeMaitre Vascular during the second quarter valued at approximately $58,000. Finally, SG Americas Securities LLC purchased a new position in shares of LeMaitre Vascular during the second quarter valued at approximately $177,000. 84.64% of the stock is currently owned by institutional investors.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.